



## Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 2, 2019

**Live Audio Webcast will be on January 7, 2019**

SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on Monday, Jan. 7, 2019, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.



The live presentation will be webcast and may be accessed on the Company's website under Investors at [www.neurocrine.com](http://www.neurocrine.com). A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

### **About Neurocrine Biosciences, Inc.**

Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed and markets INGREZZA<sup>®</sup> (valbenazine) capsules, the first FDA-approved product indicated for the treatment of adults with tardive dyskinesia, an involuntary movement disorder. Discovered and developed through Phase II clinical trials by Neurocrine, ORLISSA<sup>™</sup> (elagolix), the first FDA-approved oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for women's health. Neurocrine's clinical development programs include opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in Parkinson's disease patients, elagolix for uterine fibroids with AbbVie, valbenazine for the treatment of Tourette syndrome, and NBI-74788 for the treatment of congenital adrenal hyperplasia (CAH). For more information and the latest updates from Neurocrine Biosciences, please visit [www.neurocrine.com](http://www.neurocrine.com).

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-300772055.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Navjot Rai (Media & Investors), 858-617-7623, [IR@neurocrine.com](mailto:IR@neurocrine.com)